Role of the IL-12/IL-35 balance in patients with Sjögren syndrome

Journal of Allergy and Clinical Immunology

Volumn 142, Issue 1, 2018, Pages 258-268.e5

  Fogel, Olivier ^a   Rivière, Elodie ^a   Seror, Raphaèle ^a   Nocturne, Gaetane ^a   Boudaoud, Saida ^a   Ly, Bineta ^a   Gottenberg, Jacques Eric ^b   Le Guern, Véronique ^c   Dubost, Jean Jacques ^d   Nititham, Joanne ^e   Taylor, Kimberly E ^e   Chanson, Philippe ^f   Dieudé, Philippe ^g   Criswell, Lindsey A ^e   Jagla, Bernd ^h   Thai, Alice ⁱ   Mingueneau, Michael ⁱ   Mariette, Xavier ^a   Miceli Richard, Corinne ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c université Paris Cité   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Physiopathologie Endocrinienne et Métabolique   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSTITUT PASTEUR   (France)

ⁱ BIOGEN   (United States)

Author keywords

IL 12; IL 35; regulatory B cell; regulatory T cell; Sj gren syndrome

Indexed keywords

EBV INDUCED GENE PROTEIN 3; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P70; INTERLEUKIN 35; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; IL12A PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; B LYMPHOCYTE; CELL SELECTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SJOEGREN SYNDROME; BLOOD; GENETICS; IMMUNOLOGY; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SJOGREN'S SYNDROME;

EID: 85031108452     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.07.041     Document Type: Article

References (68)

1. Fox, R.I., Sjögren's syndrome. Lancet 366 (2005), 321–331.
2. Nocturne, G., Mariette, X., Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 9 (2013), 544–556.
3. Gottenberg, J.-E., Cagnard, N., Lucchesi, C., Letourneur, F., Mistou, S., Lazure, T., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 103 (2006), 2770–2775.
4. Emamian, E.S., Leon, J.M., Lessard, C.J., Grandits, M., Baechler, E.C., Gaffney, P.M., et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 10 (2009), 285–296.
5. Chiche, L., Jourde-Chiche, N., Whalen, E., Presnell, S., Gersuk, V., Dang, K., et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 66 (2014), 1583–1595.
6. Hall, J.C., Casciola-Rosen, L., Berger, A.E., Kapsogeorgou, E.K., Cheadle, C., Tzioufas, A.G., et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 109 (2012), 17609–17614.
7. Arshanapalli, A., Shah, M., Veerula, V., Somani, A.-K., The role of type I interferons and other cytokines in dermatomyositis. Cytokine 73 (2015), 319–325.
8. Farrar, J.D., Smith, J.D., Murphy, T.L., Murphy, K.M., Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. J Biol Chem 275 (2000), 2693–2697.
9. Rogge, L., D'Ambrosio, D., Biffi, M., Penna, G., Minetti, L.J., Presky, D.H., et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 161 (1998), 6567–6574.
10. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R.M., Clark, S.C., Chan, S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170 (1989), 827–845.
11. Sieburth, D., Jabs, E.W., Warrington, J.A., Li, X., Lasota, J., LaForgia, S., et al. Assignment of genes encoding a unique cytokine (IL12) composed of two unrelated subunits to chromosomes 3 and 5. Genomics 14 (1992), 59–62.
12. Lessard, C.J., Li, H., Adrianto, I., Ice, J.A., Rasmussen, A., Grundahl, K.M., et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 45 (2013), 1284–1292.
13. van Wanrooij, R.L.J., Zwiers, A., Kraal, G., Bouma, G., Genetic variations in interleukin-12 related genes in immune-mediated diseases. J Autoimmun 39 (2012), 359–368.
14. Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007), 566–569.
15. Niedbala, W., Wei, X.-Q., Cai, B., Hueber, A.J., Leung, B.P., McInnes, I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37 (2007), 3021–3029.
16. Collison, L.W., Chaturvedi, V., Henderson, A.L., Giacomin, P.R., Guy, C., Bankoti, J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 11 (2010), 1093–1101.
17. Devergne, O., Birkenbach, M., Kieff, E., Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 94 (1997), 12041–12046.
18. Wang, R.-X., Yu, C.-R., Dambuza, I.M., Mahdi, R.M., Dolinska, M.B., Sergeev, Y.V., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 20 (2014), 633–641.
19. Shen, P., Roch, T., Lampropoulou, V., O'Connor, R.A., Stervbo, U., Hilgenberg, E., et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507 (2014), 366–370.
20. Dixon, K.O., van der Kooij, S.W., Vignali, D.A.A., van Kooten, C., Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members. Eur J Immunol 45 (2015), 1736–1747.
21. Vosters, J.L., Landek-Salgado, M.A., Yin, H., Swaim, W.D., Kimura, H., Tak, P.P., et al. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum 60 (2009), 3633–3641.
22. McGrath-Morrow, S., Laube, B., Tzou, S.-C., Cho, C., Cleary, J., Kimura, H., et al. IL-12 overexpression in mice as a model for Sjögren lung disease. Am J Physiol Lung Cell Mol Physiol 291 (2006), L837–L846.
23. Airoldi, I., Di Carlo, E., Pistoia, V., The enigmatic role of interleukin-12 in the pathogenesis of Sjögren's syndrome: comment on the article by Vosters et al. Arthritis Rheum, 62, 2010, 2180 author reply 2180-1.
24. Collison, L.W., Delgoffe, G.M., Guy, C.S., Vignali, K.M., Chaturvedi, V., Fairweather, D., et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13 (2012), 290–299.
25. Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H.M., Alexander, E.L., Carsons, S.E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002), 554–558.
26. Seror, R., Ravaud, P., Bowman, S.J., Baron, G., Tzioufas, A., Theander, E., et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 69 (2010), 1103–1109.
27. Dieudé, P., Guedj, M., Wipff, J., Avouac, J., Fajardy, I., Diot, E., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 60 (2009), 225–233.
28. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., Reich, D., Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38 (2006), 904–909.
29. Li, Y., Zhang, K., Chen, H., Sun, F., Xu, J., Wu, Z., et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet 45 (2013), 1361–1365.
30. Miceli-Richard, C., Comets, E., Loiseau, P., Puechal, X., Hachulla, E., Mariette, X., Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum 56 (2007), 3989–3994.
31. Nordmark, G., Kristjansdottir, G., Theander, E., Appel, S., Eriksson, P., Vasaitis, L., et al. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome. Genes Immun 12 (2011), 100–109.
32. Gestermann, N., Mekinian, A., Comets, E., Loiseau, P., Puechal, X., Hachulla, E., et al. STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun 11 (2010), 432–438.
33. Korman, B.D., Alba, M.I., Le, J.M., Alevizos, I., Smith, J.A., Nikolov, N.P., et al. Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun 9 (2008), 267–270.
34. Nordmark, G., Kristjansdottir, G., Theander, E., Eriksson, P., Brun, J.G., Wang, C., et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes Immun 10 (2009), 68–76.
35. Kubin, M., Chow, J.M., Trinchieri, G., Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 83 (1994), 1847–1855.
36. Kano, S., Sato, K., Morishita, Y., Vollstedt, S., Kim, S., Bishop, K., et al. The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T cells. Nat Immunol 9 (2008), 34–41.
37. Unutmaz, D., Vilcek, J., IRF1: a deus ex machina in TH1 differentiation. Nat Immunol 9 (2008), 9–10.
38. Horiuchi, M., Yamano, S., Inoue, H., Ishii, J., Nagata, Y., Adachi, H., et al. Possible involvement of IL-12 expression by Epstein-Barr virus in Sjögren syndrome. J Clin Pathol 52 (1999), 833–837.
39. Manoussakis, M.N., Boiu, S., Korkolopoulou, P., Kapsogeorgou, E.K., Kavantzas, N., Ziakas, P., et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 56 (2007), 3977–3988.
40. Ohyama, Y., Nakamura, S., Matsuzaki, G., Shinohara, M., Hiroki, A., Fujimura, T., et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 39 (1996), 1376–1384.
41. Macatonia, S.E., Hosken, N.A., Litton, M., Vieira, P., Hsieh, C.S., Culpepper, J.A., et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154 (1995), 5071–5079.
42. Rusakiewicz, S., Nocturne, G., Lazure, T., Semeraro, M., Flament, C., Caillat-Zucman, S., et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med, 5, 2013, 195ra96.
43. Szodoray, P., Alex, P., Jonsson, M.V., Knowlton, N., Dozmorov, I., Nakken, B., et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117 (2005), 168–176.
44. Seror, R., Nocturne, G., Lazure, T., Hendel-Chavez, H., Desmoulins, F., Belkhir, R., et al. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. Arthritis Res Ther, 17, 2015, 241.
45. Li, X., Mai, J., Virtue, A., Yin, Y., Gong, R., Sha, X., et al. IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS One, 7, 2012, e33628.
46. Bardel, E., Larousserie, F., Charlot-Rabiega, P., Coulomb-L'Herminé, A., Devergne, O., Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 181 (2008), 6898–6905.
47. Li, Y., Wang, Y., Liu, Y., Wang, Y., Zuo, X., Li, Y., et al. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators Inflamm, 2014, 2014, 136329.
48. Ouyang, H., Shi, Y.-B., Liu, Z.-C., Wang, Z., Feng, S., Kong, S.-M., et al. Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci 348 (2014), 156–161.
49. Yang, Y., Xuan, M., Zhang, X., Zhang, D., Fu, R., Zhou, F., et al. Decreased IL-35 levels in patients with immune thrombocytopenia. Hum Immunol 75 (2014), 909–913.
50. Nakano, S., Morimoto, S., Suzuki, S., Tsushima, H., Yamanaka, K., Sekigawa, I., et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology (Oxford) 54 (2015), 1498–1506.
51. Nocturne, G., Virone, A., Ng, W.-F., Le Guern, V., Hachulla, E., Cornec, D., et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren's Syndrome. Arthritis Rheumatol 68 (2016), 977–985.
52. Mingueneau, M., Boudaoud, S., Haskett, S., Reynolds, T.L., Nocturne, G., Norton, E., et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 137 (2016), 1809–1821.e12.
53. Gottenberg, J.-E., Lavie, F., Abbed, K., Gasnault, J., Le Nevot, E., Delfraissy, J.-F., et al. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun 24 (2005), 235–242.
54. Li, X., Li, X., Qian, L., Wang, G., Zhang, H., Wang, X., et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome. J Rheumatol 34 (2007), 2438–2445.
55. Christodoulou, M.I., Kapsogeorgou, E.K., Moutsopoulos, N.M., Moutsopoulos, H.M., Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol 173 (2008), 1389–1396.
56. Sarigul, M., Yazisiz, V., Bassorgun, C.I., Ulker, M., Avci, A.B., Erbasan, F., et al. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjogren's syndrome. Lupus 19 (2010), 138–145.
57. Mauri, C., Bosma, A., Immune regulatory function of B cells. Annu Rev Immunol 30 (2012), 221–241.
58. Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., Anderton, S.M., B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3 (2002), 944–950.
59. Bouaziz, J.-D., Yanaba, K., Tedder, T.F., Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224 (2008), 201–214.
60. Nutz, A., Audo, R., Guilpain, P., Combe, B., Hahne, M., Morel, J., et al. Les précurseurs des lymphocytes B régulateurs présentent des anomalies quantitatives et qualitatives chez les patients atteints de syndrome de Sjögren primaire. Rev Rhumatol, 82S, 2015, A121.
61. Rosser, E.C., Mauri, C., Regulatory B cells: origin, phenotype, and function. Immunity 42 (2015), 607–612.
62. Volchenkov, R., Brun, J.G., Jonsson, R., Appel, S., In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome. Arthritis Res Ther, 15, 2013, R114.
63. Yanagi, K., Haneji, N., Hamano, H., Takahashi, M., Higashiyama, H., Hayashi, Y., In vivo role of IL-10 and IL-12 during development of Sjögren's syndrome in MRL/lpr mice. Cell Immunol 168 (1996), 243–250.
64. Tomcik, M., Zerr, P., Palumbo-Zerr, K., Storkanova, H., Hulejova, H., Spiritovic, M., et al. Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology (Oxford) 54 (2015), 2273–2282.
65. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma 29 (2013), 15–21.
66. Lawrence, M., Huber, W., Pagès, H., Aboyoun, P., Carlson, M., Gentleman, R., et al. Software for computing and annotating genomic ranges. PLoS Comput Biol, 9, 2013, e1003118.
67. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15, 2014, 550.
68. Anders, A., Huber, W., Differential expression analysis for sequence count data. Genome Biol, 11, 2010, 106.